ArticleInfectious diseases and therapy2024

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.

Colleen S Kraft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.